Implementation of HIV Pre-exposure Prophylaxis (PrEP): A Demonstration Project

Trial Profile

Implementation of HIV Pre-exposure Prophylaxis (PrEP): A Demonstration Project

Completed
Phase of Trial: Phase IV

Latest Information Update: 04 Oct 2017

At a glance

  • Drugs Emtricitabine/tenofovir disoproxil fumarate (Primary)
  • Indications HIV-1 infections
  • Focus Therapeutic Use
  • Acronyms PrEP Demonstration Project
  • Most Recent Events

    • 04 Oct 2017 Results assessing kidney function in individuals in expanding PrEP roll-out cohort treated with emtricitabine/tenofovir disoproxil fumarate, were published in the JAIDS.
    • 08 Aug 2013 Planned End Date changed from 1 Aug 2014 to 1 Dec 2014 as reported by ClinicalTrials.gov.
    • 15 Jul 2013 Planned number of patients changed from 500 to 600 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top